Mirum Pharmaceuticals: Nothing Stops This Train (But The Technicals) [Seeking Alpha]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
MIRM's liver disease franchise underpins management's new $630–$650M sales guidance for FY 2026. Pipeline catalysts—volixibat (PSC/PBC), MRM-3379 (Fragile X), and brelovitug (HDV)—offer billion-dollar-plus potential and multiple near-term data readouts. I rate MIRM a long-term, five-year HOLD, but would not add at current levels; a tactical entry might be preferable after a technical pullback or support line retest. mi-viri/iStock via Getty Images Mirum Pharmaceuticals ( MIRM ) just reported its 4Q, its full year topline clocking in at $521 million , up 55% from the prior year. Though the quarter's net income disappointed, the call cemented a banner year and provided This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of MIRM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I h
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta VirusBusiness Wire
- Mirum Pharmaceuticals (MIRM) was given a new $126.00 price target by Evercore Inc.MarketBeat
- A Look At Mirum Pharmaceuticals (MIRM) Valuation After Volatile Trading On Common Stock Offering News [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $115.00 to $117.00. They now have a "buy" rating on the stock.MarketBeat
MIRM
Earnings
- 2/25/26 - Miss
MIRM
Sec Filings
- 2/25/26 - Form S-3ASR
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- MIRM's page on the SEC website